ASCO 2020 Insights on Lymphoma: An Interview with Dr. Jacob Soumerai
Jacob Soumerai, MD, an oncologist at Massachusetts General Hospital, shared his insights on featured lymphoma research from ASCO 2020.
Related Articles
Integrating Patient-Reported Outcomes Into Prognostication in Gastroesophageal Cancer: Results of a Population-Based Retrospective Cohort Analysis
The prognostic value of the ESAS tool is unknown in gastroesophageal cancer. This study examined the association between the ESAS score and overall surviva
The Oncologist
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies,…
The Oncologist
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies,…
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
This study evaluated the association between insurer (commercial vs Medicaid) and the use of high-priced cancer treatments. Commercially insured and Medica
Renaming Palliative Cancer Therapies: Call It What It Is
This commentary explores the language choices that oncology providers make when discussing cancer therapy goals.
Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS
This report examines darolutamide tolerability from extended follow-up for both the double-blind and open-label treatment periods of the phase III ARAMIS t
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer With Actionable Driver Oncogenes
This is the largest study to date to evaluate the clinical impact of different timing and treatment patterns of first-line targeted therapy in patients with…
Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic
This study evaluated patient and disease characteristics, treatment, and prognosis of male breast cancer among patients registered with the Complex Oncological
A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating “BRCAness” Genotype (ROAR)
This article reports clinical trial results of a phase II trial assessing the efficacy of rucaparib in patients with high-risk biochemically recurrent nonmetast
Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review
The data reported here will inform treatment decision-making about the use of combination therapies that include trifluridine/tipiracil in the first-, second-,